Akademska digitalna zbirka SLovenije - logo
VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • Evidence for the use of Lorista and Valsacor beyond the hypertension treatment
    Knavs Vrhunec, Polona ; Primožič, Aleša
    The renin-angiotensin-aldosterone system has a key role in the maintenance of cardiovascular homeostasis and water and electrolyte metabolism in healthy subjects as well as in several diseases, ... including hypertension, left ventricular hypertrophy and dysfunction, coronary artery disease, renal disease and congestive heart failure. These conditions are all characterised by abnormal production and activity of angiotensin II, which is a final effector of the renin-angiotensin-aldosterone system. Over the past few decades, accumulating evidence has demonstrated that antihypertensive therapy based on angiotensin II receptor blockers (ARBs) has a major role in the selective antagonism of the main pathological activities of angiotensin II.1 Significant efforts have been made to demonstrate that blocking the angiotensin II receptor type 1 (AT1) through ARB-based therapy results in therapeutic benefits in different clinical settings. Clinical studies performed with Krkaʼs losartan (Lorista*) and valsartan (Valsacor*) and their fixed-dose combinations with hydrochlorothiazide have provided further evidence that blocking of AT1 contributes not only to the efficacy and tolerability of the treatment of hypertension but also to the reduction of the cardiovascular risk across the cardiovascular continuum.
    Vir: Evidence-based therapy with Krka's medicines (Str. 26-37)
    Vrsta gradiva - prispevek na konferenci
    Leto - 2014
    Jezik - angleški
    COBISS.SI-ID - 3765361

Vnos na polico